Document is current
Any future updates will be listed below
-
Authors
Ryan, Feargal J. https://orcid.org/0000-0002-1565-4598
Clarke, Michelle https://orcid.org/0000-0001-9635-8784
Lynn, Miriam A.
Benson, Saoirse C.
McAlister, Sonia
Giles, Lynne C.
Choo, Jocelyn M.
Rossouw, Charné
Ng, Yan Yung
Semchenko, Evgeny A. https://orcid.org/0000-0002-5188-7946
Richard, Alyson
Leong, Lex E. X.
Taylor, Steven L.
Blake, Stephen J.
Mugabushaka, Joyce I. https://orcid.org/0000-0001-8168-1976
Walker, Mary
Wesselingh, Steve L.
Licciardi, Paul V. https://orcid.org/0000-0001-6086-6285
Seib, Kate L. https://orcid.org/0000-0002-7094-3528
Tumes, Damon J. https://orcid.org/0000-0001-5709-857X
Richmond, Peter https://orcid.org/0000-0001-7562-7228
Rogers, Geraint B.
Marshall, Helen S.
Lynn, David J. https://orcid.org/0000-0003-4664-1404
- License Information
-
More Information
Article History
Received: 21 November 2023
Accepted: 17 February 2025
First Online: 2 April 2025
Competing interests
: D.J.L., S.J.B., F.J.R. and M.A.L. have received funding from GSK related to this area of research. D.J.L. and H.S.M. are consultants for GPN Vaccines (Australia). H.S.M. is an investigator on sponsored vaccine trials funded by Iliad and Pfizer. H.S.M. has received institutional funding for investigator-led studies from Pfizer, Sanofi-Aventis and Seqiris. P.R. has received institutional funding for investigator-led grants from Merck and Sanofi outside this work. His institution receives funding for his participation in vaccine scientific advisory boards from Pfizer, Merck, GSK, GPN Vaccines (Australia) and Sanofi-Aventis unrelated to this work. He is an investigator on sponsored vaccine trials funded by Iliad, GSK, Merck, Sanofi, Dynavax and Pfizer. He is coinventor on a patent for a new bacteriotherapy for treating or preventing respiratory infection unrelated to this work. The other authors declare no competing interests.
